WeVote
Log In

Bill

Bill

SB 222

Right to Try Amendments

2026 General Session Introduced by Tyler Clancy and 1 co-sponsor

SB 222 modifies Utah's Right to Try law governing terminally ill patients' access to unapproved experimental medications and medical devices.

Governor Signed
#healthcare #healthandhumanservices
0
WeVote Research Nonpartisan
Bill Summary · SB 222

Legislative bill overview

SB 222 amends Utah's Right to Try law, which allows terminally ill patients to access experimental treatments not yet approved by the FDA. The bill modifies existing provisions governing how patients access these unapproved drugs, biologics, and devices, though the specific amendments aren't detailed in the legislative record provided.

Why this is important

Right to Try laws address a fundamental tension in medical regulation: balancing patient autonomy and hope against safety safeguards designed to protect vulnerable populations. These amendments could expand or restrict access to experimental therapies for Utahns facing terminal diagnoses, affecting their treatment options and potentially influencing how other states approach similar legislation.

Potential points of contention

  • Patient access vs. safety standards: Expanding Right to Try access may limit data collection on experimental treatments, potentially missing harmful side effects that benefit future patients
  • Manufacturer liability and incentives: Clarifying or changing liability protections could affect whether pharmaceutical companies participate, directly impacting drug availability for eligible patients
  • Definition of "terminal illness": Amendments may alter eligibility criteria, determining which patients qualify and potentially excluding those with longer life expectancies but serious conditions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.